Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Telix
Telix
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Illuccix
Gallium
2021-12-17
Positron-emission tomography
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Girentuximab
non-muscle invasive bladder neoplasms
,
urologic neoplasms
,
transitional cell carcinoma
,
clear cell adenocarcinoma
,
adenomyoepithelioma
,
neoplasms
,
urinary bladder neoplasms
,
hepatocellular carcinoma
,
cholangiocarcinoma
,
von hippel-lindau disease
,
breast neoplasms
,
triple negative breast neoplasms
,
colorectal neoplasms
,
pancreatic ductal carcinoma
,
non-small-cell lung carcinoma
,
stomach neoplasms
,
esophageal neoplasms
,
nasopharyngeal carcinoma
,
lung neoplasms
,
sarcoma
,
glioblastoma
,
squamous cell carcinoma of head and neck
,
liver neoplasms
,
uterine cervical neoplasms
,
small cell lung carcinoma
,
adenocarcinoma
,
malignant mesothelioma
,
ovarian epithelial carcinoma
,
nasopharyngeal neoplasms
,
mesothelioma
,
renal cell carcinoma
,
carcinoma
,
kidney neoplasms
,
recurrence
,
neuroendocrine tumors
Phenylalanine
multiple myeloma
,
plasma cell neoplasms
Riboprine
carcinoma
,
squamous cell carcinoma of head and neck
,
squamous cell carcinoma
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use